Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad
Gilead Sciences Inc., of Foster City, Calif., has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity.
Gilead acquired cicletanine from Navitas Assets LLC in 2008 for a $10.9 million up-front payment and milestones. The drug is approved in some European countries for hypertension.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter